Request Demo
Last update 13 May 2026
BC-006
Last update 13 May 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms ADG125, BC-006, BC006 |
Target |
Action antagonists |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 319501096CDR2-L
Sequence Code 431762733CDR1-H
Sequence Code 432628977CDR2-H
Sequence Code 432629055CDR3-H
Sequence Code 756220516CDR1-L
Sequence Code 756220519CDR3-L
Sequence Code 756220526VH
Sequence Code 756220536VL
Sequence Code 788347768L
Sequence Code 788347770H
Related
4
Clinical Trials associated with BC-006NCT07447102
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BC006 in Patients With Idiopathic Pulmonary Fibrosis
ISRCTN83576037
A Phase II, randomized, double-blind, placebo-controlled, combination therapy trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of subcutaneous injections of BC-006 and tirzepatide in adults with obesity
ISRCTN18176375
A phase 1, randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a subcutaneous injection of BC-006 in adults with obesity- part 2
100 Clinical Results associated with BC-006
Login to view more data
100 Translational Medicine associated with BC-006
Login to view more data
100 Patents (Medical) associated with BC-006
Login to view more data
100 Deals associated with BC-006
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Phase 2 | - | 01 Apr 2026 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 18 Sep 2021 | |
| Giant Cell Tumor of Tendon Sheath | Phase 1 | China | 18 Sep 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free